CLINICAL TRIAL

Axitinib for Sarcoma, Alveolar Soft Part

Waitlist Available · Any Age · All Sexes · Miami, FL

This study is evaluating whether a drug called Axitinib can be used to treat cancer.

See full description

About the trial for Sarcoma, Alveolar Soft Part

Eligible Conditions
Soft Tissue Sarcoma (STS) · Sarcoma · Sarcoma, Alveolar Soft Part · Alveolar Soft Part Sarcoma (ASPS)

Treatment Groups

This trial involves 2 different treatments. Axitinib is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

Experimental Group 1
Axitinib
DRUG
+
Pembrolizumab
DRUG
Experimental Group 2
Axitinib
DRUG
+
Pembrolizumab
DRUG

About The Treatment

Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Axitinib
FDA approved
Pembrolizumab
FDA approved

Eligibility

This trial is for patients born any sex of any age. There are 10 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
clear cell sarcoma
chordoma.
synovial sarcoma
malignant peripheral nerve sheath tumors
dedifferentiated, pleomorphic or myxoid/round cell liposarcoma
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Up to 5 years
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Up to 5 years.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Axitinib will improve 2 primary outcomes and 8 secondary outcomes in patients with Sarcoma, Alveolar Soft Part. Measurement will happen over the course of 3 Months.

Percentage of Evaluable Participants Achieving Progression-Free Survival (PFS) at 3 Months
3 MONTHS
Percentage of participants who are disease progression free 3 months after initiation of therapy. Disease progression will be evaluated from imaging measures using the Response Evaluation Criteria for Solid Tumors (RECIST) 1.1.
Rate of Participants Achieving Progression-Free Survival (PFS) at 3 Months
3 MONTHS
Rate of participants who are disease progression free 3 months after initiation of therapy. Disease progression will be evaluated from imaging measures using the Response Evaluation Criteria for Solid Tumors (RECIST) 1.1.
Number of Participants Experiencing Serious Adverse Events (SAEs), Dose-Limiting Toxicities, and Grade 3 or Higher Treatment-Emergent Adverse Events
UP TO 25 MONTHS
The number of participants experiencing serious adverse events (SAEs), dose-limiting toxicities (DLTs), and grade 3 or higher treatment-emergent adverse events (AEs). AEs, SAEs and DLTs will be evaluated by treating physician using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03. Treatment-emergent adverse events are those found to be definitely, probably and possibly related to study therapy.
Percentage of Evaluable Participants Achieving Clinical Benefit Response (CBR)
UP TO 2 YEARS
CBR is defined as achieving complete response (CR), partial response (PR) or stable disease (SD) from imaging measures using (RECIST) 1.1.
Time to Progression (TTP)
UP TO 2 YEARS
Time to progression (TTP) is defined as time from treatment initiation to first occurrence of progression by Response Evaluation Criteria for Solid Tumors (RECIST) 1.1 or death.
Percentage of Evaluable Participants Achieving Objective Response Rate (ORR)
UP TO 2 YEARS
Objective Response Rate (ORR) is defined as achieving complete response (CR) or partial response (PR) from imaging measures using (RECIST) 1.1.
See More

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does axitinib usually treat?

Axitinib is used to treat lung cancer, gastric cancer, colorectal cancer, and renal cell carcinoma. Patients whose tumors are positive for BRAF or NRAS mutations can benefit from axitinib.

Anonymous Patient Answer

What is sarcoma, alveolar soft part?

The sarcoma, alveolar soft part is a rare tumor. Its appearance on palpation most closely mimics that of a malignant fibrous tumor. These tumors have their origins in the mesothelium of the alveolar sacs, alveolar glands, or bone, and have a tendency towards local recurrence. The sarcoma, alveolar soft part is easily diagnosed on radiographs. The diagnosis of the sarcoma, alveolar soft part is based on the histological type, which in this case consists of the epithelial component. Treatment depends on the type of tumor.

Anonymous Patient Answer

What causes sarcoma, alveolar soft part?

The most common causes of sarcoma, alveolar soft part tumours involve radiation or an acute viral infection, both the main risk factors for cancers occurring of many tissues. The link between radiation and sarcoma is the first recognised example of a radiation-cancer relationship (except in breast cancer), despite the long history of ionising radiation use. Knowledge of the precise causal agents and ways of transmission that occur can help prevent further incidents of cancer.

Anonymous Patient Answer

What are the signs of sarcoma, alveolar soft part?

Symptoms of sarcoma, alveolar soft part include weight loss, induration, edema, and pain along the bone or joint. Symptoms can cause significant impairment in the ability to function.\n

Anonymous Patient Answer

Can sarcoma, alveolar soft part be cured?

Findings from a recent study show that it is possible to have a cure in this case. It depends on the stage of the tumor and on the type of treatment, but it is possible.

Anonymous Patient Answer

How many people get sarcoma, alveolar soft part a year in the United States?

Each year, around 36,820 new cases of sarcoma, excluding leiomyosarcoma and soft tissue sarcoma, will be diagnosed in the US; excluding leiomyosarcoma and soft tissue sarcoma, this number is around 34,620. Sarcoma, excluding sarcomas of unknown origin, is thus the most common primary tumor of the soft tissue in US adults. However, this lesion is relatively rare when the whole cancer population is taken into account, comprising only 1.96% of all cancers in the USA in 2010. However, the incidence of sarcoma is markedly higher in men than in women, especially in the 30- to 49-year age group.

Anonymous Patient Answer

What are common treatments for sarcoma, alveolar soft part?

In this article, sarcoma, alveolar soft part, and soft part sarcoma are shown to have similar treatments that are mainly administered as palliative care options. Newer, more aggressive, or investigational treatments are the most likely to be found in the literature. More research on specific sarcoma and soft part sarcoma populations may be needed for more accurate treatment decisions.

Anonymous Patient Answer

What is the average age someone gets sarcoma, alveolar soft part?

There was no significant difference in the mean age at diagnosis between gender and race/ethnicity. There was no significant difference between sex and age groups or by race/ethnicity. There was no significant difference between sex and race/ethnicity. There was no significant difference between gender and age groups. Sex accounted for a significant amount of the variation in cancer severity and stage at diagnosis. The incidence and prevalence of sarcoma, alveolar soft part was significantly higher in Hispanics (P=0.003) and Latinos (P<0.00).

Anonymous Patient Answer

Does sarcoma, alveolar soft part run in families?

Sarcoma, alveolar soft part is an X-linked dominant disease. To confirm one diagnosis, it is best to have both parents tested and to have a panel of tests including multiplex PCR, fluorescent in situ hybridization, and direct sequencing.

Anonymous Patient Answer

What are the chances of developing sarcoma, alveolar soft part?

There are two groups of patients with potential for developing sarcoma, alveolar soft part. The patients with a [prior history of [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer)] seem to develop sarcoma, alveolar soft part at a higher rate than non-lung cancer patients without a prior lung cancer. In a recent study, findings need to be verified with more patients but show a [possible correlation of prior lung cancer with sarcoma, alveolar soft part] to evaluate further and confirm possible risks and [correlations of prior non-cancer-related sarcoma with sarcomas other than lung carcinoma] to evaluate the true incidence of sarcomas in non-lung cancer patients.

Anonymous Patient Answer

What is the survival rate for sarcoma, alveolar soft part?

Survival after definitive surgical treatment of sarcoma, alveolar soft part is excellent. Long-term survival is also possible with the new adjuvant treatment approaches. Survival depends on the specific tumor and can vary from months to more than 10 years.

Anonymous Patient Answer

What is the latest research for sarcoma, alveolar soft part?

The latest research into sarcoma, alveolar soft part showed promise that it can be treated with targeted therapy for metastatic disease in a nonirradiated setting. The data are consistent with reports of clinical activity with targeted therapy.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Sarcoma, Alveolar Soft Part by sharing your contact details with the study coordinator.